---
title: "Linzess (linaclotide) in irritable bowel syndrome with constipation: Clinical trials questions"
description: "Clinical trials questions on Linzess (linaclotide) in irritable bowel syndrome with constipation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results and Pediatric efficacy. Questions: How were the Linzess adult IBS-C trials designed (Trials 1 and 2)? Linzess vs placebo in adult IBS-C: how many responded for 9 of 12 weeks? Linzess vs placebo in adult IBS-C: how many responded for 6 of 12 weeks? How soon does Linzess improve IBS-C abdominal pain and constipation in adults? 4 further questions follow. 8 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Linzess (linaclotide) in irritable bowel syndrome with constipation: Clinical trials questions

Manufacturer: AbbVie, Inc.; Ironwood Pharmaceuticals, Inc.  
Prescribing information: [Linzess](https://www.rxabbvie.com/pdf/linzess_pi.pdf)

Questions that apply to every indication of Linzess are on [Linzess (linaclotide), all indications](https://www.evicenter.com/medical-information/linzess).

## Study results

<a id="linzess-adult-trial-design"></a>

### How were the Linzess adult IBS-C trials designed (Trials 1 and 2)?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “The efficacy of LINZESS for the treatment of IBS-C was established in two double-blind, 
> placebo-controlled, randomized, multicenter trials in adult patients (Trials 1 (NCT00948818) 
> and 2 (NCT00938717)). A total of 800 patients in Trial 1 and 804 patients in Trial 2 [overall 
> mean age of 44 years (range 18 to 87 years), 90% female, 77% white, 19% black, and 12% 
> Hispanic] received treatment with LINZESS 290 mcg or placebo once daily and were 
> evaluated for efficacy. All patients met Rome II criteria for IBS and were required, during the 2-”

Source: [LINZESS: Prescribing information, page 14, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=14)

> “week baseline period, to meet the following criteria:”

Source: [LINZESS: Prescribing information, page 14, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=14)

> “• a mean abdominal pain score of at least 3 on a 0-to-10-point numeric rating scale 
> • less than 3 complete spontaneous bowel movements (CSBMs) per week [a CSBM is a 
> spontaneous bowel movement (SBM) that is associated with a sense of complete 
> evacuation; a SBM is a bowel movement occurring in the absence of laxative use], and  
> • less than or equal to 5 SBMs per week.  
>
> The trial designs were identical through the first 12 weeks, and thereafter differed only in that 
> Trial 1 included a 4-week randomized withdrawal (RW) period, and Trial 2 continued for 14 
> additional weeks (total of 26 weeks) of double-blind treatment. During the trials, patients were 
> allowed to continue stable doses of bulk laxatives or stool softeners but were not allowed to 
> take laxatives, bismuth, prokinetic agents, or other drugs to treat IBS-C or chronic constipation.”

Source: [LINZESS: Prescribing information, page 15, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=15)

<a id="linzess-adult-9-of-12-week-response"></a>

### Linzess vs placebo in adult IBS-C: how many responded for 9 of 12 weeks?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “The 4 primary efficacy responder endpoints were based on a patient being a weekly responder 
> for either at least 9 out of the first 12 weeks of treatment or at least 6 out of the first 12 weeks 
> of treatment. For the 9 out of 12 weeks combined primary responder endpoint, a patient had to 
> have at least a 30% reduction from baseline in mean abdominal pain, at least 3 CSBMs and an 
> increase of at least 1 CSBM from baseline, all in the same week, for at least 9 out of the first 
> 12 weeks of treatment. Each of the 2 components of the 9 out of 12 weeks combined 
> responder endpoint, abdominal pain and CSBMs, was also a primary endpoint.”

Source: [LINZESS: Prescribing information, page 15, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=15)

> “In both trials, the proportion of patients who were 
> responders to LINZESS 290 mcg was statistically significantly higher than with placebo.”

Source: [LINZESS: Prescribing information, page 15, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=15)

> “Table 3:  
> Efficacy Responder Rates in Two Placebo-Controlled Trials of Adults with 
> IBS-C (Trials 1 and 2): At Least 9 Out of 12 Weeks”

Source: [LINZESS: Prescribing information, page 15, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=15)

> “Trial 1 
> Trial 2 
>
> LINZESS 
> 290 mcg 
> Once 
> Daily 
> (N=405) 
> Placebo 
> (N=395) 
> Treatment 
> Difference 
> [95% CI] 
> LINZESS 
> 290 mcg 
> Once 
> Daily 
> (N=401) 
> Placebo 
> (N=403) 
> Treatment 
> Difference 
> [95% CI] 
> Combined 
> Responder* 
> (Abdominal Pain 
> and CSBM 
> Responder) 
> 12% 
> 5% 
> 7% 
> [3.2%, 
> 10.9%] 
> 13% 
> 3% 
> 10% 
> [6.1%, 
> 13.4%] 
> Abdominal 
> Pain 
> Responder*  
> (≥ 30% 
> Abdominal 
> Pain 
> Reduction)  
> 34%  
> 27% 
> 7% 
> [0.9%, 
> 13.6%] 
> 39%  
> 20% 
> 19% 
> [13.2%, 
> 25.4%] 
> CSBM 
> Responder* 
> (≥ 3 CSBMs 
> and Increase 
> ≥1 CSBM from 
> Baseline) 
> 20%  
> 6% 
> 13% 
> [8.6%, 
> 17.7%] 
> 18%  
> 5% 
> 13% 
> [8.7%, 
> 17.3%] 
> * Primary Endpoints 
> Note: Analyses based on first 12 weeks of treatment for both Trials 1 and 2 
> CI =Confidence Interval”

Source: [LINZESS: Prescribing information, page 16, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=16)

Note: Table 3 columns are, for Trial 1 and then Trial 2, LINZESS 290 mcg once daily, placebo, and the treatment difference with its 95% CI, in that order; results are for the first 12 weeks of treatment.

<a id="linzess-adult-6-of-12-week-response"></a>

### Linzess vs placebo in adult IBS-C: how many responded for 6 of 12 weeks?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “For the 6 out of 12 weeks combined primary responder endpoint, a patient had to have at least 
> a 30% reduction from baseline in mean abdominal pain and an increase of at least 1 CSBM 
> from baseline, all in the same week, for at least 6 out of the first 12 weeks of treatment. To be 
> considered a responder for this analysis, patients did not have to have at least 3 CSBMs per 
> week.”

Source: [LINZESS: Prescribing information, page 15, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=15)

> “The efficacy results for the 9 out of 12 weeks and the 6 out of 12 weeks responder endpoints 
> are shown in Tables 3 and 4, respectively. In both trials, the proportion of patients who were 
> responders to LINZESS 290 mcg was statistically significantly higher than with placebo.”

Source: [LINZESS: Prescribing information, page 15, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=15)

> “Table 4:  
> Efficacy Responder Rates in Two Placebo-Controlled Trials of Adults with 
> IBS-C (Trials 1 and 2): At Least 6 Out of 12 Weeks 
>
>
> Trial 1 
> Trial 2 
> LINZESS 
> 290 mcg 
> Once 
> Daily 
> (N=405) 
> Placebo 
> (N=395) 
> Treatment 
> Difference 
> [95% CI] 
> LINZESS 
> 290 mcg 
> Once 
> Daily 
> (N=401) 
> Placebo 
> (N=403) 
> Treatment 
> Difference 
> [95% CI] 
> Combined 
> Responder* 
> (Abdominal Pain 
> and CSBM 
> Responder) 
> 34% 
> 21% 
> 13% 
> [6.5%, 
> 18.7%] 
> 34% 
> 14% 
> 20% 
> [14.0%, 
> 25.5%] 
> Abdominal Pain 
> Responder** 
> (≥ 30% 
> Abdominal Pain 
> Reduction) 
> 50% 
> 37% 
> 13% 
> [5.8%, 
> 19.5%] 
> 49% 
> 34% 
> 14% 
> [7.6%, 
> 21.1%] 
> CSBM 
> Responder** 
> (Increase ≥ 1 
> CSBM from 
> Baseline) 
> 49% 
> 30% 
> 19% 
> [12.4%, 
> 25.7%] 
> 48% 
> 23% 
> 25% 
> [18.7%, 
> 31.4%] 
> * Primary Endpoint, ** Secondary Endpoints  
> Note: Analyses based on first 12 weeks of treatment for both Trials 1 and 2 
> CI =Confidence Interval”

Source: [LINZESS: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=17)

Note: Table 4 columns are, for Trial 1 and then Trial 2, LINZESS 290 mcg once daily, placebo, and the treatment difference with its 95% CI, in that order; results are for the first 12 weeks of treatment.

<a id="linzess-adult-onset"></a>

### How soon does Linzess improve IBS-C abdominal pain and constipation in adults?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “In each IBS-C trial, maximum effect on CSBM frequency was reached within the first week of treatment with LINZESS and was maintained until the end of the trial”

Source: [LINZESS: Efficacy For Patients With IBS-C | LINZESS® (linaclotide) | For HCPs, captured 2026-11-14](https://www.linzesshcp.com/linzess-ibs-c-efficacy#:~:text=In%20each%20IBS%2DC%20trial%2C%20maximum,the%20end%20of%20the%20trial)

> “Maximum effect on abdominal pain was seen at weeks 6 to 9 of treatment with LINZESS and was maintained until the end of the study”

Source: [LINZESS: Efficacy For Patients With IBS-C | LINZESS® (linaclotide) | For HCPs, captured 2026-11-14](https://www.linzesshcp.com/linzess-ibs-c-efficacy#:~:text=Maximum%20effect%20on%20abdominal%20pain,the%20end%20of%20the%20study)

> “In each trial, improvement from baseline in abdominal pain and CSBM frequency was seen 
> over the first 12-weeks of the treatment periods. For change from baseline in the 11-point 
> abdominal pain scale, LINZESS 290 mcg began to separate from placebo in the first week. 
> Maximum effects were seen at weeks 6 - 9 and were maintained until the end of the study. The 
> mean treatment difference from placebo at week 12 was a decrease in pain score of 
> approximately 1.0 point in both trials (using an 11-point scale). Maximum effect on CSBM 
> frequency occurred within the first week, and for change from baseline in CSBM frequency at 
> week 12, the difference between placebo and LINZESS was approximately 1.5 CSBMs per 
> week in both trials.”

Source: [LINZESS: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=17)

<a id="linzess-adult-stool-straining"></a>

### Does Linzess improve stool consistency and straining in adults with IBS-C?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “In each trial, in addition to improvements in abdominal pain and CSBM frequency over the first 
> 12 weeks of the treatment period, improvements were observed in the following when 
> LINZESS was compared to placebo: SBM frequency [SBMs/week], stool consistency [as 
> measured by the Bristol Stool Form Scale (BSFS)], and amount of straining with bowel 
> movements [amount of time pushing or physical effort to pass stool].”

Source: [LINZESS: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=17)

Note: These results are from Trials 1 and 2 (LINZESS 290 mcg vs placebo, first 12 weeks); the label gives no figures for these endpoints.

<a id="linzess-adult-stopping"></a>

### What happens when adults with IBS-C stop Linzess (Trial 1 withdrawal)?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “During the 4-week randomized withdrawal period in Trial 1, patients who received LINZESS 
> during the 12-week treatment period were re-randomized to receive placebo or continue 
> treatment on LINZESS 290 mcg. In LINZESS-treated patients re-randomized to placebo, 
> CSBM frequency and abdominal-pain severity returned toward baseline within 1 week and did 
> not result in worsening compared to baseline. Patients who continued on LINZESS maintained 
> their response to therapy over the additional 4 weeks. Patients on placebo who were allocated 
> to LINZESS had an increase in CSBM frequency and a decrease in abdominal pain levels that 
> were similar to the levels observed in patients taking LINZESS during the treatment period.”

Source: [LINZESS: Prescribing information, page 18, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=18)

<a id="linzess-adult-bloating-trial-6"></a>

### Does Linzess improve the overall abdominal score (bloating, pain, discomfort) in adult IBS-C (Trial 6)?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “In a phase 3b trial, LINZESS improved overall abdominal symptoms (bloating, pain, discomfort) in adult patients with IBS-C<sup>1,2</sup>”

Source: [LINZESS: Efficacy For Patients With IBS-C | LINZESS® (linaclotide) | For HCPs, captured 2026-11-14](https://www.linzesshcp.com/linzess-ibs-c-efficacy#:~:text=In%20a%20phase%203b%20trial%2C,discomfort%29%20in%20adult%20patients%20with)

> “Trial 6 (NCT03573908) was a randomized, double-blind, placebo-controlled, parallel-group trial 
> that evaluated the safety and efficacy of LINZESS in patients with IBS-C over a 12-week 
> treatment period followed by a 4-week randomized withdrawal period. A total of 614 patients 
> [mean age of 47 years (range 18 to 85 years), 81% female, 63% white, 24% black, and 27% 
> Hispanic] received treatment with LINZESS 290 mcg or placebo once daily and all patients met 
> Rome III criteria for IBS-C.  
>
> The efficacy of LINZESS was assessed using a primary endpoint based on the mean 
> abdominal score (composite of abdominal bloating, abdominal discomfort, and abdominal pain) 
> across 12 weeks. The secondary endpoint was a responder analysis based on at least a 2.5-
> point improvement in the abdominal score from baseline for at least 6 out of 12 weeks as 
> shown in Table 5.”

Source: [LINZESS: Prescribing information, page 18, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=18)

> “Table 5:  
> Efficacy Endpoints in a Placebo-Controlled Trial of Adults with IBS-C (Trial 
> 6): Overall Change from Baseline in Abdominal Score and Responder Rates 
> for at Least 6 Out of 12 Weeks  
>
>
>
> Trial 6 
>
> LINZESS  
> 290 mcg 
> Once Daily 
> (N=306) 
> Placebo 
> (N=308) 
> Treatment Difference 
> [95% CI] 
> Baseline Abdominal Score 
> 6.4 
> 6.5 
> - 
> Least Squares 12-week Mean 
> Change from Baseline in 
> Abdominal Score*  
> -1.9 
> -1.2 
> -0.7 [-1.0, -0.4] 
> Abdominal Score 6 of 12-Week 
> Responder** 
> 34% 
> 18.5% 
> 15.5% [8.6%, 22.3%] 
> * Primary Endpoint, ** Secondary Endpoint 
> Each abdominal symptom was rated on a 0-to-10-point numeric rating scale where 0=no [symptom] and 
> 10=worst possible [symptom]. 
> CI = Confidence Interval”

Source: [LINZESS: Prescribing information, page 18, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=18)

> “Reduction from baseline in abdominal score was significantly greater for LINZESS compared with placebo starting at week 1.<sup>3</sup>”

Source: [LINZESS: Efficacy For Patients With IBS-C | LINZESS® (linaclotide) | For HCPs, captured 2026-11-14](https://www.linzesshcp.com/linzess-ibs-c-efficacy#:~:text=Reduction%20from%20baseline%20in%20abdominal,with%20placebo%20starting%20at%20week)

Note: Table 5 columns are LINZESS 290 mcg once daily (N=306), placebo (N=308), and the treatment difference with its 95% CI, in that order. The abdominal score is a composite of bloating, discomfort, and pain. The week 1 statement is cited on the page to the published Trial 6 report (Chang et al., Am J Gastroenterol 2021); the Prescribing Information does not report weekly results for Trial 6.

## Pediatric efficacy

<a id="linzess-pediatric-efficacy"></a>

### How effective is Linzess for IBS-C in children 7 to 17 (Trial 8)?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in pediatric patients 7 years of age and older

> “The efficacy of LINZESS for the treatment of IBS-C in pediatric patients 7 to 17 years of age 
> was established in a 12-week double-blind, parallel-group, randomized, multicenter, clinical 
> trial (Trial 8; NCT04026113). A total of 108 patients were randomized to receive treatment with 
> LINZESS 145 mcg once daily or a higher than recommended dosage of LINZESS. The higher 
> LINZESS dosage group did not demonstrate additional treatment benefit compared to 
> LINZESS 145 mcg once daily. A total of 53 patients who received LINZESS 145 mcg once 
> daily were evaluated for efficacy. The evaluated patients had a mean age of 13 years (range 7 
> to 17 years); 57% were female; 34% identified as Hispanic or Latino; 72% identified as White, 
> 25% as Black or African American, and 4% as Asian.”

Source: [LINZESS: Prescribing information, page 19, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=19)

> “The primary endpoint was the proportion of patients who achieved at least a 30% reduction in 
> abdominal pain and an increase of at least 2 spontaneous bowel movements (SBMs)/week 
> from baseline for at least 6 out of 12 weeks (combined responder). The result of the primary 
> efficacy endpoint is shown in Table 6. 
> Table 6:  
> Efficacy Responder Rate in Pediatric Patients 7 to 17 Years of Age with 
> IBS-C (Trial 8): At Least 6 out of 12 Weeks   
> Trial 8  
> LINZESS 145 mcg  
> Once Daily 
> n (%) 
> [95% CI] 
> N=53  
> Combined Responder†  
> (Abdominal Pain and SBM 
> Responder) 
> 16 (30%)  
> [18%, 44%] 
>
> Abdominal Pain Responder 
> (≥ 30% Abdominal Pain 
> Reduction) 
> 36 (68%) 
> SBM Responder  
> (Increase ≥ 2 SBMs from 
> Baseline) 
> 21 (40%)”

Source: [LINZESS: Prescribing information, page 19, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=19)

> “<sup>†</sup> The primary endpoint of combined responder is defined as a patient who has at least a 30% reduction in 
> abdominal pain and an increase of at least 2 SBMs/week from baseline for at least 6 out of 12 weeks.”

Source: [LINZESS: Prescribing information, page 20, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=20)

> “Abdominal pain and SBM frequency improved during week 1 and improvement was 
> maintained throughout the remainder of the 12-week treatment period.”

Source: [LINZESS: Prescribing information, page 20, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=20)

> “Use of LINZESS for this indication is supported by 
> evidence from adequate and well-controlled studies in adults and pediatric patients 7 to 17 
> years of age.”

Source: [LINZESS: Prescribing information, page 10, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=10)

Note: Trial 8 randomized patients to LINZESS 145 mcg once daily or a higher than recommended dosage, as the first passage states. The label describes no placebo group in Trial 8; the responder rates in Table 6 are for the 145 mcg group (N=53) over 12 weeks and have no comparator, and the week 1 statement describes change from baseline.

## Related pages
- [Medical information: Linzess (linaclotide): Irritable bowel syndrome with constipation](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation)
- [Safety](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/safety)
- [Specific populations](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/guidelines)
